Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Setmelanotide

Obesity Weekly News

Obesity Today—May 12, 2026

This week’s Obesity update highlights regulatory actions, access shifts,…

Obesity Weekly News

Obesity Today—March 31, 2026

This week’s Obesity update highlights regulatory progress, advancing late-stage…

Obesity Weekly News

Obesity Today—March 24, 2026

This week’s Obesity update highlights regulatory progress, advancing clinical…

Obesity Weekly News

Obesity Video Recap—March 3, 2026

This biweekly Obesity video recap highlights late-stage combination data,…

Obesity Weekly News

Obesity Weekly News - August 26th 2025

Viking’s Crash, Orforglipron’s Rise, Semaglutide CV Data, SlimBiome Deal &…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
LucidWargames
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Respiratory Today—May 15, 2026
Vaccines Today—May 15, 2026
Public Health Today—May 15, 2026
Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology Research Sites
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License

Tags

AAAAI 2025 ADA Standards of Care american college of cardiology Asundexian BIA brain tumors calluna pharma cancer care cancer neuroscience cancer vaccines Chiesi Rare Diseases Clinical immunology combinations competitive advantage Enavogliflozin facial rejuvenation FDA endocrinology approvals gi oncology Gosta Labs Headache disorders HeartFlow Helicobacter pylori Hematology market trends home collection Hutchinson-Gilford Progeria syndrome iPSC therapy Mycobacterium Avium Complex Lung Disease Na-GST 1/Al-CpG OneTouch Vita Ovarian Function Suppression Pain Pancreatic ductal adenocarcinoma peptide therapeutics Peptinov Portable AI Eye Scanner radiation oncology Relapsing-remitting multiple sclerosis SKYRIZI Tecvayli TIMP-3 gene therapy tirbanibulin Tobramycin transdermal GLP/GIP triple agonist VLA15

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Respiratory Today—May 15, 2026
Vaccines Today—May 15, 2026
Public Health Today—May 15, 2026
Lucid Diligence Brief: Iterative Health Acquisition of NextStage Cardiology Research Sites
Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License

TAGS

AAAAI 2025 ADA Standards of Care american college of cardiology Asundexian BIA brain tumors calluna pharma cancer care cancer neuroscience cancer vaccines Chiesi Rare Diseases Clinical immunology combinations competitive advantage Enavogliflozin facial rejuvenation FDA endocrinology approvals gi oncology Gosta Labs Headache disorders HeartFlow Helicobacter pylori Hematology market trends home collection Hutchinson-Gilford Progeria syndrome iPSC therapy Mycobacterium Avium Complex Lung Disease Na-GST 1/Al-CpG OneTouch Vita Ovarian Function Suppression Pain Pancreatic ductal adenocarcinoma peptide therapeutics Peptinov Portable AI Eye Scanner radiation oncology Relapsing-remitting multiple sclerosis SKYRIZI Tecvayli TIMP-3 gene therapy tirbanibulin Tobramycin transdermal GLP/GIP triple agonist VLA15

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy